Patient information guide

Finasteride and dutasteride sexual side effects

Finasteride and dutasteride can affect sexual desire, erection or ejaculation. Discuss the purpose of treatment and the timing of any change with your prescriber.

How the medicines act
Testosterone
Starting hormone.
5-alpha reductase
The enzyme inhibited by these medicines.
DHT
The hormone produced by this conversion.
On this page

If your desire, erections or ejaculation change during treatment, make a note of when you first noticed it. The doses used for hair loss and prostate enlargement can differ. Bring the medicine name, dose and a list of your other treatments so the prescriber can consider what might have contributed.

Finasteride and dutasteride are drugs that suppress the 5-alpha reductase enzyme. They reduce the conversion of testosterone to dihydrotestosterone (DHT). DHT is an androgen effective in tissues associated with male pattern hair loss and prostate enlargement. The 1 mg oral form of finasteride used for hair loss and the 5 mg form used for prostate enlargement are not prescribed for the same clinical purpose. Dutasteride suppresses different 5-alpha reductase isoenzymes. Indications for use and license status by country should be evaluated.

These medications are not testosterone replacement therapy. A decrease in DHT does not mean that total testosterone has decreased to pathological levels in every patient. Sexual symptoms related to treatment cannot be explained solely on the basis of testosterone results.

Changes in desire, erections and ejaculation

Decreased sexual desire, erectile dysfunction, and ejaculation changes have been reported during use of finasteride and dutasteride in clinical studies. A decrease in ejaculate volume may be observed in some patients. However, since the same symptoms can also occur in people taking placebo, the difference between the drug group and the control group should be evaluated in studies.

41 studies were included in the systematic review published in 2026 examining 5-alpha reductase inhibitors in the treatment of androgenetic alopecia. In some of the placebo-controlled studies for oral finasteride 1 mg, sexual side effects were 1.9–6.7% in the treatment group. It was reported in the range of 0.9–3.9% in the placebo groups. In dutasteride 0.5 mg studies, ranges were given as 4.1–12% in the treatment groups and 4–5% in the placebo. These percentages are not a single combined risk estimate from the same study. Is the range of rates reported by different studies. The doses, durations and patient selection of the studies vary. (Systematic review of sexual adverse effects of 5-alpha reductase inhibitors for hair loss)

Therefore, a definitive estimate that ‘a certain percentage of men using finasteride will definitely develop erectile dysfunction’ is not correct. The frequency of symptoms may vary depending on the form used, indication, age, comorbidities and measurement method of the study.

Does hair loss treatment and prostate treatment carry the same risk?

Men using finasteride for hair loss are often younger. In men using 5-alpha reductase inhibitors due to prostate enlargement, age and accompanying vascular, metabolic or urinary health problems may be more evident. Therefore, it is misleading to directly compare the sexual symptom rates of different patient groups.

Additionally, a combination with alpha blockers can be used to treat prostate enlargement. Some alpha blockers may also affect ejaculation patterns. The entire drug list should be considered when evaluating which treatment the symptom may be related to in a man using concomitant medications.

Symptoms that continue after stopping

In randomised studies, most sexual side effects resolved when treatment was discontinued or, in some individuals, while treatment continued. However, sexual symptoms that continue after stopping the drug have been reported. It is not right to ignore these declarations completely.

The term ‘post-finasteride syndrome’ is used for sexual, psychological and sometimes physical symptoms that are reported to persist after treatment has been discontinued. However, it has not yet been shown that the symptoms collected under this nomenclature occur with a single biological mechanism, that there is a specific test for diagnosis, or that the frequency of occurrence can be calculated reliably.

A 2026 systematic review found that research on persistent symptoms relies heavily on self-report and observational data. It emphasizes that definition, selection and control group differences create uncertainty. (Systematic review of sexual adverse effects of 5-alpha reductase inhibitors for hair loss)

This clinical uncertainty does not mean that the symptoms a person is experiencing are unimportant. If the symptom has started, its timing, pre-existing sexual function, mental state, other medications, sleep and metabolic risks should be examined together. When necessary, alternatives are discussed with the treating physician.

Warnings about mood and mental health

In May 2025 the European Medicines Agency (EMA) confirmed suicidal thoughts as a side effect of finasteride 1 mg and 5 mg tablets. How often it happens is unknown. The review found no proven causal link with dutasteride. A precaution was added to the dutasteride information because the medicines belong to the same class. The EMA concluded that the benefits of both medicines continue to outweigh their risks for approved uses. (EMA safety review of finasteride and dutasteride, May 2025)

In May 2026 the UK Medicines and Healthcare products Regulatory Agency (MHRA) updated its warnings about sexual side effects, depression and suicidal thoughts. It advises anyone taking finasteride 1 mg who develops depression or suicidal thoughts to stop taking it and contact a healthcare professional promptly. Anyone taking finasteride 5 mg or dutasteride who develops these symptoms should seek medical advice immediately. (MHRA updated safety warnings on finasteride and dutasteride, May 2026)

These warnings do not mean that mental problems will develop in every user. On the other hand, pre-treatment evaluation and follow-up are important, especially in people with a history of depression. If there is a risk of self-harm, immediate help should be sought.

Semen analysis and plans to have children

Male fertility cannot be measured by erection or sexual desire alone. Sperm production, semen volume and motility of sperm cells are separate biological outcomes.

In a double-blind, randomised study published by Amory et al. in 2007, 99 healthy men used dutasteride 0.5 mg, finasteride 5 mg, or placebo for one year. At the sixth month, a decrease in total sperm count compared to baseline was reported in the dutasteride and finasteride groups. Some differences at later time points did not reach statistical significance. A decrease in semen volume was also observed in the dutasteride group. (Amory et al., randomized study of finasteride, dutasteride and semen parameters, 2007)

This research shows that some semen parameters may be affected. But the 5 mg finasteride dose in the study is not the same as the 1 mg used for hair loss. Moreover, the change in semen parameters is not directly equivalent to the possibility of natural pregnancy or live birth.

Medication history should be specifically questioned in men who are planning to have children, have a previous abnormal semen analysis, or are undergoing an infertility evaluation. Routine semen analysis is not mandatory for every user. The examination is planned according to the clinical context.

Do these medicines work like testosterone?

No. Exogenously administered testosterone can significantly reduce sperm production by suppressing the hypothalamic-pituitary-testicular axis. Finasteride and dutasteride target the conversion of testosterone to DHT. Their effects on reproductive health should not be explained by the same mechanism.

Interpreting a PSA result

Finasteride and dutasteride may affect prostate volume and serum PSA level. According to the EAU male lower urinary tract symptoms guideline, 5-alpha reductase inhibitors can reduce PSA by approximately 50% after six to twelve months of treatment. (EAU Guidelines on Male LUTS: Disease Management)

Therefore, it is not appropriate to interpret the PSA result of a man using the medication in the same context as someone not using the medication. EAU follow-up recommendations include determining a new PSA baseline value at six months and evaluating confirmed PSA increases during treatment. (EAU Guidelines on Male LUTS: Follow-up)

Instead of automatically correcting PSA with a single coefficient, treatment duration, previous PSA values and individual risk for prostate cancer should be evaluated together. The patient must declare the finasteride or dutasteride used during the PSA test.

What to discuss if symptoms start

In the first evaluation, it is important to consider when the symptom started, whether there is a change in the drug dose, and sexual function before starting the drug. Erectile dysfunction, decreased libido, changes in ejaculation and genital sensation symptoms should be questioned separately.

Diabetes, hypertension, smoking, depressive symptoms, sleep disorders, and concomitant medications may also affect sexual function. It would not be right to attribute all the symptoms to a single drug without investigating these reasons. However, the possible contribution of the drug should not be ignored.

If there are clinical findings suggestive of hypogonadism, measurement of total testosterone in the morning may be appropriate. However, it has not been shown that an extensive hormone panel should be performed in every man using finasteride.

The continuation of treatment, dose or choice of alternatives should be evaluated with the relevant physician according to the characteristics of the hair disease or prostate problem. High dose supplements, ‘DHT restoration’ protocols or unsupervised hormone use recommended on the internet are not a proven solution.

Why the medicines are prescribed

Finasteride and dutasteride are medications used for certain diseases. It is not used to slow down aging. The changes they cause in androgen metabolism do not indicate a reversal of biological age. On the other hand, sexual function and reproductive plan should be taken into account in the long-term health goals of the person when making treatment decisions.

The better question is not whether the drug is overall ‘good’ or ‘bad’. It is how to balance the expected clinical benefit for a particular patient with known and potential risks.

Common questions

Does finasteride cause erectile dysfunction?

Erectile dysfunction has been reported in some men. In placebo-controlled studies, this symptom may also be seen in placebo recipients. Possible drug-related effects should be evaluated together with other reasons.

Does sexual function improve when finasteride is stopped?

Most sexual side effects in studies may regress, but there are also symptoms that have been reported to persist after treatment. Uncertainty remains regarding the true frequency and mechanisms of persistence.

Is dutasteride riskier than finasteride?

The enzyme suppression properties and areas of use of the two drugs are different. Direct individual risk comparisons should not be made because side effect percentages, patient characteristics, and doses are not the same in different studies.

Does finasteride lower sperm count?

Changes in semen parameters have been reported in some randomised studies. The effect is not the same for everyone. In men with a fertility plan, medication use should be discussed with the physician.

Does finasteride for hair loss affect PSA?

5-alpha reductase inhibitors may alter PSA levels. The physician requesting the test must be aware of the medication used.

What should you do if you develop depressive symptoms while using finasteride?

The medicine safety advice differs by dose. If depression or suicidal thoughts develop while taking finasteride 1 mg, stop taking it and contact a healthcare professional without delay. Seek emergency help if there is an immediate risk of self-harm.


During the discussion about these medications, prostate enlargement and PSA or semen analysis results may come up, depending on your reason for use.

Related reading

Medication use and new symptoms are evaluated with the physician who issued the prescription. If mental symptoms occur, follow the safety warnings above, which vary depending on the drug and dose used.

Sources6 sources

Cookies required for site functions are always on. You can choose the other categories.

CallWhatsAppAppointment